Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Dare Bioscience is a biotechnology business based in the US. Dare Bioscience shares (DARE) are listed on the NASDAQ and all prices are listed in US Dollars. Dare Bioscience employs 20 staff and has a trailing 12-month revenue of around $10 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $1.24 |
|---|---|
| 52-week range | $0.82 - $1.88 |
| 50-day moving average | $0.97 |
| 200-day moving average | $1.10 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.56 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.24 from 2023-02-01
| 1 week (2023-01-26) | -8.82% |
|---|---|
| 1 month (2022-12-30) | 49.40% |
| 3 months (2022-11-02) | 22.77% |
| 6 months (2022-08-02) | 6.90% |
| 1 year (2022-02-01) | -22.01% |
|---|---|
| 2 years (2021-02-02) | -41.09% |
| 3 years (2020-01-31) | 10.70% |
| 5 years (2018-02-02) | 2.175 |
| Revenue TTM | $10 million |
|---|---|
| Gross profit TTM | $-100,000 |
| Return on assets TTM | -31.13% |
| Return on equity TTM | -84.31% |
| Profit margin | -245.47% |
| Book value | $0.31 |
| Market capitalisation | $115.4 million |
TTM: trailing 12 months
We're not expecting Dare Bioscience to pay a dividend over the next 12 months.
Dare Bioscience's shares were split on a 1:10 basis on 19 July 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dare Bioscience shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Dare Bioscience shares which in turn could have impacted Dare Bioscience's share price.
Over the last 12 months, Dare Bioscience's shares have ranged in value from as little as $0.82 up to $1.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dare Bioscience's is 1.1904. This would suggest that Dare Bioscience's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Daré Bioscience, Inc. , a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.